Brief: Arca Biopharma Inc Says Believes That Its Current Cash And Cash Equivalents Will Be Sufficient To Fund Its Operations Through Middle Of 2023
14/03/2022 20:24
March 14 (Reuters) - ARCA Biopharma Inc ABIO.O :
* ARCA BIOPHARMA INC- BELIEVES THAT ITS CURRENT CASH AND
CASH
EQUIVALENTS, WILL BE SUFFICIENT TO FUND ITS OPERATIONS THROUGH
MIDDLE OF 2023
Source text for Eikon: ID:nGNX1cKBDb
Further company coverage: ABIO.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Oruka Therapeutics
See all newsOruka falls after reporting mid-stage data for psoriasis drug
Brief: Oruka Therapeutics Announces Positive Week 28 Data For Orka-001 From The Ongoing Everlast-A Trial Showing Deepening Of Responses Without Additional Dosing
Brief: Oruka Therapeutics Appoints Todd Edwards As Chief Commercial Officer
U.S. RESEARCH ROUNDUP-Accendra Health, Celestica, Sionna Therapeutics
Oruka Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary